Multiple tobacco product (MTP) users represent a sizable minority of tobacco users: Estimates from the Population Assessment of Tobacco and Health (PATH) Study indicate that 37.8% of adult tobacco users-10% of the US adult population overall-are current users of two or more tobacco products.
Introduction
Tobacco use is the leading cause of death and disability in the United States. Combusted cigarette (CC) smoking alone accounts for 480 000 deaths annually; whereas, for every person who dies as a result of smoking, at least 30 people (ie, >16 million Americans) are living with smoking-related disease. 1 Moreover, smoking is responsible for more than $300 billion annually in medical care and lost productivity. and cigarillos (5%); CC and smokeless tobacco, excluding snus (4%) and; CC and traditional cigars (4%). 2 According to data from the National Survey on Drug Use and Health (NSDUH), the prevalence of MTP use has remained stable between 2002 and 2011 (25.9% vs. 23 .5% of tobacco users; 8.7% vs. 7.4% of the general population). 3 However, an increase in MTP was observed during this period among youth (23.5% vs. 29.0%) and young-adult (21.4% vs. 23.7%) tobacco users, even as overall tobacco use has declined. 4, 5 It should be noted that the NSDUH is limited to assessing CC, cigars, and smokeless tobacco, and does not evaluate the use of increasingly popular tobacco products such as hookah and ENDS. This probably explains the discrepancy in MTP prevalence between PATH-which assesses a wider variety of tobacco-product use-and NSDUH data sets.
Stable (among adults) and increasing (among youth/young adults) prevalence of MTP use among tobacco users is likely due to, in part, increases in the diversity, marketing, and distribution of non-CC tobacco products. For example, youth MTP users were found to have higher exposure to tobacco-product marketing than CC-only users. 6 During the past decade, sales 7 and use 5 of CC have declined, but sales of non-CC tobacco products like cigars and loose tobacco, 7 moist snuff, 7, 8 and ENDS 9 have increased. Accordingly, use of little cigars, 10 smokeless tobacco, pipe tobacco, 7 and ENDS 11, 12 have increased over time. A significant proportion (31%) of MTP use involves ENDS. 2 The prevalence of MTP use in the United States is significant given that it is associated with greater nicotine exposure 13, 14 (though also see references 15 and 16) and dependence 17 and difficulty with tobacco cessation as compared with single tobacco product (STP) use. 13, 18 Though findings often vary based on the type (ie, dual ENDS/CC vs. CC/cigar use) of MTP-use combinations and number of products (ie, dual vs. poly-tobacco-product use (concurrent use of >2 products) under consideration, research shows that MTP users often smoke a comparable 19 or greater number of CC per day 15, 19, 20 as compared to CC-only users. In one study, dual CC/cigar and CC/ ENDS users were significantly more likely to report greater tobacco withdrawal and craving versus CC-only users. 19 MTP use has been found to be associated with a greater likelihood of nicotine dependence versus CC-only use. 19, 20 Furthermore, in youth, poly-tobacco use is associated with greater nicotine dependence 21 and decreased likelihood of intention to quit 22 as compared to dual users. Finally, adult MTP users have been found to be more likely to report cessation intentions, 19 make a cessation attempt, 10, 23 or have made a greater number of attempts 18, 20 (though see reference 24) than STP users. However, MTP use is associated with a shorter time to relapse 10 and a decreased likelihood of cessation.
18,24-26

MTP Use and FDA Tobacco Regulatory Control
In 2009, the Family Smoking Prevention and Tobacco Control Act (TCA) 27 gave the Food and Drug Administration (FDA) the power to regulate the manufacture, marketing, and distribution of tobacco products in ways that protect and improve public health. Although the TCA does not specifically mention MTP use, several aspects of the TCA suggest the need for a more concentrated and comprehensive assessment of the use of MTPs and the potential effects of regulatory actions on MTP use. We focus here specifically on two FDA regulatory principles: consideration of the population as a whole and consideration of actual tobacco-product use.
Considering the Population as a Whole
One measure of the TCA gives the FDA authority to set new standards for tobacco products if they are "appropriate for the protection of public health" based on the evidence of the "risks and benefits to the population as a whole, including users and nonusers of tobacco products" (emphasis added). As noted above, a sizable minority of tobacco-product users use MTPs, which in turn also means that a significant number of nonusers are affected by MTP use via their association with MTP users. Moreover, STP users are influenced by an increasingly diverse tobacco-product market and regulation of that market may increase their interest in, and use of, more than one tobacco product. It is worth noting, however, that product substitution and/or MTP use may have positive effects in some instances (eg, among CC users who are unable to quit using nicotine products and subsequently transition to EC use). Regardless, any assessment of the risks and benefits to the "population as a whole" of any FDA regulatory action must take into account the potential risks and benefits to current and future MTP users.
Considering "actual use"
Under the TCA, the FDA may allow a manufacturer of a tobacco product to market their product with a claim that it confers reduced risk of disease relative to other commercially available tobacco products (ie, that it is a "modified risk tobacco product" (MRTP)). 28 In order to allow such "modified risk claims," the manufacturer must demonstrate that the product significantly reduces harm to individual tobacco users "as it is actually used by consumers," including an analysis of the "increased or decreased likelihood that existing users of tobacco products who would otherwise stop using such products will switch to the tobacco product that is the subject of the application." Though it is possible that existing tobacco users who would adopt the use of an MRTP may transition entirely to the use of that product, in practice, it is likely that some proportion of existing tobacco-product users who adopt the use of an MRTP would become MTP users. For instance, a CC smoker might be attracted to a new tobacco product marketed as a less harmful option than CC but might reduce rather than eliminate their use of CC with the MRTP.
Regulatory Action by Non-FDA Authorities
The framework proposed here focuses specifically on the effects of FDA regulation, but recognizes that other governing bodies can take regulatory actions that have an impact on MTP use. State and local governments can set taxes on tobacco products, which in turn, have an impact on their sales. 29 Nearly all states impose considerably higher excise taxes on CC than on other tobacco products, 30 which has been implicated in the increasing use of non-CC tobacco products. 31, 32 Moreover, state and local governments can set minimum buying age and ban specific characteristics of tobacco products (eg, flavored products).
Conceptual Framework
In this paper, we present a conceptual framework for understanding factors that contribute to the use of MTPs (Figure 1 ). Our framework includes Person, Product, and Context/Situation factors (and their interactions) that influence tobacco-product use. The framework is meant to be useful in understanding the mechanisms that lead to MTP use in the first place and for understanding how/when MTPs are used and/or discontinued by an individual. The framework is also meant to be useful in understanding how changes in the use of any one tobacco product influence the use of other tobacco products. Illustrative examples of variables that influence MTP use under each category are described-but they are not exhaustive. In addition, the impact of MTP use on toxicant exposure and health outcomes are not considered here. Moreover, given the state of the existing literature and for the sake of simplicity and illustration, we focus the majority of our examples on dual tobacco-product use. Additionally, the focus of our conceptual framework and discussion largely applies to the use and/or adoption of MTP among current tobacco users; less attention is given to MTP use during the initiation and early experimentation with tobacco products. After describing the framework, we provide a map for how different regulatory actions target specific factors, in an effort to better understand where such actions can have influence and how such actions on one STP influence the use of other tobacco products. Our conceptual framework draws on and synthesizes elements from a number of health behavior theories (eg, Theory of Triadic Influence, 33 the Health Belief Model, 34 and Reasoned Action 35, 36 and Planned Behavior Theory 37 ) but also draws from marketing 38 and behavioral economic 39, 40 literatures.
Tobacco Product Substitution
At the core of the proposed framework is the concept that any two tobacco products vary in the degree to which they substitute for one another. We briefly review definitions for substitution below:
Behavioral Economics
Behavioral economics precisely defines substitution as occurring when increases in the unit price of one product results in an increase in consumption of another when both products are available concurrently. The degree to which one product substitutes for another is quantified by a measure known as cross-price elasticity (CPE; positive numbers = substitution). In hypothetical cross-commodity purchase tasks, ENDS have been shown to serve as substitutes for CC, and vice versa. For instance, among dual ENDS/CC users when both ENDS and CC were available concurrently, Johnson and colleagues 38 showed that as the price of CC puffs increased, purchasing of CC puffs decreased while purchasing of fixed-price ENDS puffs increased (CPE: 0.10). Conversely, as the price of ENDS puffs increased, purchasing of ENDS puffs decreased while purchasing of fixed-price CC puffs increased (CPE: 0.06). Grace and colleagues 41 found that ENDS served as a partial substitute for CC, as the CPE was significantly positive (0.16). Utilizing an experimental tobacco marketplace, Quisenberry and colleagues 42 observed that among smokers, ENDS and snus served as substitutes for CC at the highest price point for CC and that, among dual ENDS/CC, as CC price increased, purchasing of ENDS, snus, and nicotine lozenges and gum increased, with ENDS serving as a stronger substitute for CC as compared to snus or nicotine lozenges and gum. 43 O'Connor and colleagues 44 showed that snus, dissolvable tobacco products, and nicotine lozenges serve as weak substitutes for CC (CPE: 0.26-0.33). Additionally, a recent systematic review and meta-analysis found that CC may act as substitute for ENDS, nicotine patch, and pipe tobacco, while functioning as a weak complementary good (ie, the demand for CC decreased as the price of non-CC tobacco products increased) for smokeless and rollyour-own tobacco. 45 CC with a very low nicotine content have also been shown to potentially serve as partial substitutes for CC (CPE: 0.32).
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Behavioral Pharmacology
In behavioral pharmacology research, one product substitutes for another when the availability or provision of one product decreases craving for, or the use of, another product. Multiple studies have examined the impact of the use of one nicotine-containing product on the use of other products. Johnson and colleagues 47 examined how hard smokers would work (eg, press buttons on a computer mouse) to gain access to nicotine gum, when the amount of work needed to gain access to puffs of CC increased. As the amount of work necessary for gaining access to CC increased, smokers worked more for nicotine gum (the work to obtain gum was held constant). Lesser amounts of work for nicotine-containing CC was necessary for smokers to work for nicotine-free CC suggesting they are a better substitute for nicotine-containing CC than nicotine gum.
Studies have also examined the substitutability of tobacco products, such as ENDS, for CC in both laboratory and naturalistic settings. In laboratory settings, for instance, two studies have observed that ENDS decreased craving/urge for CC. 48, 49 In the context of more naturalistic settings, Meier and colleagues 50 observed that providing smokers with first generation ENDS for a week decreased satisfaction derived from CC and craving for CC, but did not observe significant decreases in smoking behavior, or any differences due to the provision of nicotine versus placebo ENDS. In an 8-week randomized trial, 51 smokers were assigned to smoke either very low nicotine content (VLNC) or normal nicotine content (NNC) CC, and were given access to an "experimental marketplace" in which they could purchase noncombustible tobacco products, including ENDS, snus, and medicinal nicotine. Assignment to the VLNC condition resulted in greater uptake and use of noncombusted tobacco products and higher rates of abstinence versus the NNC condition.
Self-reported Motivation
Finally, substitution is sometimes defined based on self-reported motivations for using one tobacco product versus another. Doyle and colleagues, 51 for instance, used the term substitution to describe dual users' self-reported use of ENDS to cut down on or replace their use of CC. This motivation to substitute ENDS for CC is contrasted with self-reports that ENDS use is motivated primarily by not being able to use CC in certain situations (ie, complementary use). Additional research regarding individuals' self-reported motivations for tobacco-product use is described below as is the role of Context/ Situation-specific use of products on "dynamic complementarity."
Sources of Variability in Cross-Product Substitution
A tenet of our framework is that there are Person, Product, and Context/Situation factors (and interactions between these factors) that influence the use and degree of substitution between tobacco products, which in turn begin to explain complex, and dynamic patterns of MTP use. These factors govern who uses what products, when, and for what purposes. Below, we review selected variables associated with each of these factors and the interaction between two factors (Person × Product).
Person-level Variables
Tobacco use varies as a function of a broad range of person-level variables, including nicotine dependence, nicotine metabolic rate, socioeconomic status, age, and gender. Below we review associations between MTP use and two person-level variables: demographic factors and quit motivation/intention. Demographics of MTP Use. Relatively little work has examined sociodemographic correlates of MTP use. In addition to being more likely to be tobacco-product users overall, males are more likely to be MTP users. 3, 21, 23, 52, 53 One study 3 -using US nationally representative data-found that African-American and Native Hawaiian/ Other Pacific Islander race, as well as Hispanic ethnicity were associated with a decreased likelihood of past-year MTP use, whereas Native American/Alaska Native and White race were associated with an increased likelihood of MTP use. Younger age 3,23,52,54,55 and lower socioeconomic status-as measured by educational attainment 3, 54 and income 3, 52 -are also often associated with MTP use. Quit Motivation/Intention. Research indicates that use motivations and quit intentions are correlated with the tobacco product(s) that a person uses. For instance, many dual ENDS/CC users report using ENDS to help them reduce the number of CC that they smoke. 40, [56] [57] [58] [59] Rass and colleagues 58 assessed reasons for ENDS use among dual ENDS/CC users; many reported ENDS use in order to cut down on CC smoking in preparation for a quit attempt (40%) to quit CC smoking outright (34%) and to deal with cravings for CC (57%) or withdrawal (35%). Additionally, 12% of the sample reported using ENDS in order to cut down on CC smoking with no intention to quit completely. Similar findings have been observed among dual CC/snus users 60, 61 and CC/little cigar and cigarillo users.
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Product Characteristic Variables
The tobacco marketplace is diverse, and products vary on characteristics including, but not limited to, (1) whether they are combusted or noncombusted, (2) characterizing flavor(s) and nicotine content, (3) pricing, (4) design of the product and packaging, (5) how the product is marketed and advertised, and (6) distribution and availability of products. Each of these factors influences the appeal of a product and how a user uses each product singly. Here, we focus only on two of these variables: characterizing flavors and nicotine content.
Characterizing Flavors. The availability of e-liquid in varied flavors (ie, flavors beyond tobacco/menthol) is an appealing characteristic of ENDS. 63, 64 Flavor variability is cited as a reason for ENDS experimentation, 65, 66 initiation, 67, 68 and continued use. 59, 67, 69, 70 Interviews with young adults indicate that variability of ENDS flavors was a primary reason that ENDS are more attractive products than CC. 67 Additionally, a laboratory study of young-adult ENDS users found that sweet-flavored e-liquids produced greater appeal ratings such as liking and willingness to use again compared to non-sweet (eg, tobacco) and flavorless e-liquids. 71 Little cigar and cigarillo users also often report using these products because of the availability of flavors that they like. 72 Regarding CC, under the FSPTCA, 27 menthol is the only characterizing flavor that is permitted in CC. Menthol is associated with increased initiation and progression to regular CC smoking, as well as a decreased likelihood of cessation. 73 Additionally, the taste, sensory properties, and easier smoking of menthol CC-via the anesthetic and cooling sensation properties of menthol-contribute to the appeal of menthol CC to youth. 73 Nicotine Content. The nicotine content of tobacco products contributes to their appeal. In a Cigarette Purchase Task study, CC with VLNC were less appealing than those with NNC in terms of the amount of money for which participants were willing to pay for CC. 74 E-liquids with higher nicotine concentrations tend to result in higher plasma nicotine concentrations. 75, 76 Additionally, research using 1G ENDS devices have found that nicotine-containing, as compared with nicotine-free, ENDS are more effective at reducing craving to smoke CC, 48, 77 nicotine withdrawal, 77 and CC smoked per day when used by smokers for 3 weeks. 78 Dose-dependent responses to e-liquid nicotine content are not always evident, however. Meier and colleagues 50 observed no differences in withdrawal, satisfaction, intention to quit or confidence to quit using CC, or carbon monoxide or urinary cotinine between first generation nicotine-containing versus nicotinefree ENDS. These mixed findings potentially indicate that factors in addition to nicotine content (eg, sensory components of vaping) are responsible for differential nicotine delivery, craving and withdrawal reduction, and substitution for combusted tobacco products.
Person × Product Interactions
We hypothesize that tobacco-product use is dependent on the interaction between Person-and Product-level variables. Although little data exist regarding the influence of Person × Product variables on MTP use, extensive data do exist for their influence on STP. Based on data derived from the study of STP use, we present brief examples regarding product appeal, risk perceptions, and nicotine delivery/ metabolism.
The appeal of a STP is dependent both on the characteristics/ features of the product and on the degree to which the user likes and values those characteristics and features. Perkins and colleagues, 79, 80 for instance, demonstrated that male sex (ie, Person) was associated with greater, nicotine dose-dependent (ie, Product), liking of nasal spray among nonsmokers. Likewise, the perceived risk of using a product is dependent both on characteristics of the product (eg, whether it is combustible) and the sensory impact of the product (eg, harshness), knowledge that the user has about the relative safety/ harm associated with the product, and the frequency/chronicity of product use. For instance, the physiological properties of menthol contribute to the perception of cooling, smoothness, mildness, easing of irritation, perceived lower nicotine and tar yield, and the perception that menthol CC are "less strong" versus nonmenthol CC. 73 CC with these attributes are perceived to impart reduced harm. These interacting Person (ie, risk perceptions) and Product (ie, menthol) characteristics, in turn, contribute to the use of menthol CC by smokers. 81 Additionally, providing strong evidence for Person × Product interactions, in a discrete choice experiment, adult CC smokers' demand for ENDS was found to be influenced by perceptions of ENDS safety. 82 These findings indicate that risk perceptions have the potential not only to influence the use of a STP, but also to influence the adoption and concurrent use of a lower risk product in order to decrease the harms associated with tobacco use. As a final example, the reinforcing effects of a tobacco product will likely vary as a function of the speed with which an individual metabolizes nicotine and the speed/effectiveness with which various products deliver nicotine to the bloodstream. For instance, women metabolize nicotine more quickly than men. 83 This increased metabolism (ie, Person), coupled with highly effective nicotine delivery via CC (ie, Product), probably contributes to the increased susceptibility to nicotine addiction among women and may help to explain why, among smokers, it is more difficult for women to quit. 84 Additionally, newer (ie, 2nd and 3rd generation) ENDS devices are capable of delivering nicotine more effectively, resulting in higher plasma nicotine concentrations, 85, 86 than 1st generation devices and in more effective reductions in CC craving and withdrawal symptoms.
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Reinforcement History
Product, Person, and Context/Situation factors influence the degree to which a tobacco product is reinforcing-that is, the degree to which the use of a product sustains behavior necessary for future use of a product. Nicotine is the primary psychoactive compound in tobacco products and, though a weak reinforcer relative to other drugs of abuse, 89, 90 can sustain nicotine seeking behavior in humans, rodents, and nonhuman primates. 91 Nicotine is substantially more reinforcing when administered in ways that result in acute increases in plasma levels (eg, when smoked or vaped) relative to slower routes of administration (eg, transdermal nicotine patch). 91 Nicotine may also act a secondary reinforcer by increasing the reinforcing properties of stimuli associated with it, potentially including sensory effects (eg, smell, flavor, throat impact) of the tobacco product. Finally, certain characteristics of tobacco products may be reinforcing in and of themselves. Users report, for instance, that they like (and find appealing) the sweet taste and characterizing flavors of some ENDS e-liquids, 59, 63, 64, 67, 69, 71 which may in turn reinforce the use of ENDS, even in the absence of nicotine. 71 Thus, a final tenet of the proposed framework is that use of any STP results in a history of reinforcement that not only influences future use of that product, but also influences substitutability between that and other tobacco products. The user of a STP may at some point come to experiment with another tobacco product. To the degree that that second product is reinforcing, and results in plasma nicotine levels that further reinforce the use of the product, the user may decide to decrease or discontinue their use of the first product. Such a decision may depend on other contingencies-for instance, a CC smoker may switch over to using ENDS exclusively because the latter substitutes for the former (with respect to nicotine levels) and at relatively little additional cost, but with the belief that use of ENDS is a safer form of nicotine self-administration. Each of these (cost, perceived risk) and other factors described above influence the degree to which a product is reinforcing in and of itself, and then by extension results in the either full (ie, complete substitution of one product for another) or partial (eg, dual use) substitution.
Finally, over time, and through exposure to, and experimentation with, various tobacco products, users develop complex Person-byProduct-by-Context/Situation reinforcement histories that govern who uses which tobacco products and in what contexts, and for what purposes. Adding further to these complexities, over time and through learning histories and through exposure to other information, tobacco users are constantly updating their knowledge, perceptions, and beliefs about tobacco products that may further impact on their use of any one product, and thus their use of other products. A dual user of CC and ENDS might for instance learn about a new ENDS device or e-liquid flavor that upon use they find more reinforcing than their previous ENDS, which in turn decreases their use of CC further. Such complex interactions between factors are difficult to fully capture in any single study (see section "Summary and Areas for Future Research" below on research questions) but are vital for piecing together comprehensive pictures of tobacco product use in a complex marketplace and for fully estimating the impact of how regulation of one tobacco product might impact on the use of another.
Context/Situation Variables
Contextual and situational variables (eg, presence of others smoking, use of alcohol, withdrawal level, product availability) are influential on the decision to use a tobacco product or not at any given time, 92, 93 but can also potentially influence which tobacco product a MTP user selects for use at any given time.
Among MTP users, the use of non-CC tobacco products is often associated with the inability or inconvenience of using CC in a given situation. For instance, dual ENDS/CC users have reported that they use ENDS in order to self-administer nicotine in situations in which they cannot use CC (eg, at work, indoors) 40, 58, 94 or to avoid having to go outside in order to use CC. 58 Young adults also report using non-CC tobacco products (eg, little cigars) during situations in which they have no access to CC. 95 Additionally, 45% of dual CC/ENDS users reported that they were more likely to use ENDS versus CC when around children or pregnant women. 58 Conversely, a majority of dual users reported using CC over ENDS when drinking alcohol (69%), outdoors (65%), when stressed or anxious (61%), and in hedonic contexts such as after eating (53%), when drinking coffee (53%), and after having sex (52%). 58 That different tobacco products may be used in different contexts or situations by the same user suggests that, while products vary in the degree to which they substitute for one another, products may also be "dynamic complements." 38, 51 For instance, preference for CC in one context (eg, when outdoors, in conjunction with alcohol) but ENDS in others (eg, when around children, indoors) may have the effect of increasing the value of both products (ie, complementarity) since one product (ENDS) is now associated with purposes that CC can only satisfy with additional cost (eg, hassle of having to go outside). In this way, ENDS use, since it perpetuates nicotine dependence, maintains demand for CC. Such dynamic complementarity may explain evidence that a proportion of MTP users smoke as many or more CC per day than CC-only users 15, 19, 20 -that is, for these MTP users, another tobacco product is used in addition to (ie, as a complement) rather than instead of (ie, as a substitute) for CC.
Adding to these complex relationships between product use, two tobacco products may serve both as substitutes and dynamic complements and the shifts between substitution and complementarity may itself be dynamic over time. For instance, a CC user may be attracted to and start using ENDS as a means of reducing CC use or even with the intention of quitting CC use altogether (ie, substitution). They find over time though that ENDS use complements their use of CC and thus become dual users while not decreasing (or even potentially increasing) their total nicotine intake.
Effects of Regulatory Action on MTP Use
A key feature of our framework is that it maps out where past and possible FDA regulatory actions affect MTP use by exerting influence on framework variables. We propose specifically that any regulatory action that decreases or increases the reinforcing properties of a STP can affect the use of other tobacco products by altering their cross-substitution. A new product standard, for instance, that restricts ENDS to tobacco characterizing flavors, may reduce their appeal and reinforcement and in turn, decrease their substitution for CCs. Likewise, a product standard that reduces nicotine content in CCs 27 may decrease the appeal and reinforcement of CC use and in turn, increase interest in and use of noncombusted tobacco products. As another example, MRTP designation may decrease the perceived harm associated with a tobacco product and increase its appeal and use by smokers interested in maintaining nicotine use while decreasing disease risk associated with use.
Evidence that regulation of one tobacco product influences the use of others exists. Following the enactment of the FSPTCA in 2009, findings from the National Youth Tobacco Survey showed that there was a 17% decreased likelihood of adolescents being current CC smokers and a 58% decrease in the number of CC smoked by current smokers. 96 However, the ban on characterizing flavors was also associated with increases in the use of menthol CC (use increased by 45%), cigars (by 34%), and pipes (by 55%) among current CC smokers, implying substitution toward the remaining legal flavored tobacco products. 96 Additionally, sales of flavored cigars increased by nearly 50% from 2008 to 2015, 97 and sales of clove cigars, specifically, increased by 1400% from 2009 to 2012. 8 Although some of these increases may be due to increases in marketing expenditures by tobacco companies intent on replacing lost revenue, 98 they also suggest that tobacco users will seek out substitutes following regulation of STPs.
Further evidence suggests that increasing the cost of one tobacco product can lead to substitution. 31, 99 Delnevo and colleagues 31 observed that increases in CC taxes in New Jersey resulted in significant increases in cigar use among recent quitters of CC smoking.
Hawkins and colleagues 99 found that, among adolescents, increases in CC taxes led to increased use of both cigars and smokeless tobacco. Additionally, the passage of the Children's Health Insurance Program Reauthorization Act in 2009 resulted in large federal excise tax disparities among tobacco products (ie, higher taxes on CC, small cigars, and roll-your-own tobacco, but not for pipe tobacco or large cigars). 98 This differential taxation resulted in significant increases in monthly sales of pipe tobacco and large cigars, with corresponding decreases in sales of roll-your-own tobacco and small cigars from 2009 to 2011. Although the FDA does not have jurisdiction over tobacco-product taxation, these data provide further evidence that any actions that decrease the use and appeal of one tobacco product can have the unintended consequence of increasing the use of other tobacco products.
Recent work also provides evidence that potential regulations on ENDS may have an impact on their use, as well as the use of CC. Pacek and colleagues 100 presented an online sample or youngadult dual ENDS/CC users with a variety of hypothetical scenarios regarding possible regulations that would limit the availability of flavors and nicotine content in e-liquid. By and large, these restrictions resulted in anticipated reductions in ENDS use and corresponding increases in CC use. Similarly, in the context of a discrete choice experiment, Buckell and colleagues 101 found that a hypothetical flavor ban on ENDS e-liquids resulted in increased choice for CC. Future and ongoing work will expand upon the findings from these hypothetical tasks by assessing similar questions in laboratory and clinical trials contexts.
Summary and Areas for Future Research
Despite representing 35% or more of the tobacco using population, a disproportionately small percentage of research has focused specifically on the question of MTP use. Given that MTP use is remaining stable or increasing in segments of the population and given that the FDA must consider the potential impact of regulatory actions on the population as a whole, additional and increased research is warranted. Based on our review of the literature, we propose that the field prioritize this research by focusing on the following areas: 102 Ecological momentary analysis (EMA) studies are needed to examine daily and weekly patterns of use of MTPs, the differential contexts in which MTP are used, and factors influencing the relative frequency with which different products are used. Assessment of temporal patterns at each of these scales, along with information about influencing effects of regulatory actions, can be used to better estimate the effects of such actions on health at population, group and individual levels.
Research on the effects of using one product on another.
Although an increasing number of studies have examined hypothetical cross-product substitution, surprisingly little research has experimentally evaluated the influence of using one product on the use other products. Little is known for instance regarding the effects of ENDS on CC reinforcement and the degree to which various ENDS characteristics (eg, nicotine concentration) modulate CC reinforcement. Laboratory methods are well-suited for the evaluation of static substitution (ie, how does use of Product A influence craving and use of Product B). Investigators should however, seek ways to model the more complex dynamic complementary ways in which MTPs are used in the real world. For instance, questions such as, "does alcohol influence the degree to which ENDS substitute for CCs?," can attempt to model realworld complementarity.
Research on the effects of STP regulatory actions on the use
of other tobacco products. Increasingly, experimental research has been conducted to evaluate the effects of possible tobacco regulatory actions. The Center for the Evaluation of Nicotine in Cigarettes (CENIC), for instance, has evaluated the effects of nicotine content reduction on smoking behavior and toxicant exposure. 103 However, these studies have set upper limits on the amount of non-CC tobacco use allowable for study inclusion (ie, less than 10 days/per month). As such, the impact of possible tobacco regulatory actions on CC or any other tobacco product has not been evaluated in the full spectrum of MTP users and thus little is known about how FDA or other regulatory actions might impact on what is a sizable minority of the population of tobacco users. Additional research on the impact of regulating one or more products on the use of products among representative samples of MTP users should thus be a priority. 5. Research on the health effects of MTP use. As noted above, the data diverge on whether users of CC and other tobacco products are exposed to more or less carcinogens and toxicants than CC-only smokers. 13, 15, 16, 18 In addition, only scant data to date have been evaluated on whether adoption of ENDS by CC smokers decreases carcinogen and toxicant exposure and whether such decreases are sustained over time among dual users of these products. In addition, little is known regarding whether CC-only smokers differ in their smoking topography from ENDS/CC users, or whether MTP use affects other topography patterns. Research is needed in which both (1) topography data are collected under controlled and real-world conditions and (2) biomarkers of toxicant/carcinogen exposure are assessed to evaluate these questions.
Conclusions
In this paper, we describe a novel framework from which to understand and further research MTP use. Person, Product, and Context/ Situation factors (and their interactions) contribute to variation in MTP use across individuals and time. Individual tobacco products vary in the degree to which they substitute for one another. To the degree that they are used in different contexts and/or for different purposes, they may also serve as dynamic complements. Such dynamic complementarity may explain why MTP users on average use tobacco products more frequently and are more dependent than STP users. Finally, regulation of tobacco products that targets a single product may have consequences for the use of other tobacco products dependent upon their cross-substitution. Future research should examine the complex nature of MTP within the proposed framework.
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